Format

Send to

Choose Destination
Brain Nerve. 2019 Jun;71(6):565-570. doi: 10.11477/mf.1416201317.

[Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].

[Article in Japanese]

Author information

1
Department of Neurology, Graduate School of Medicine, Chiba University.

Abstract

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction mainly caused by anti-nicotinic acetylcholine receptor (AChR) antibodies. Complements are known to play a prominent role in the pathogenesis of MG. Long-term remission may not necessarily be achieved in MG patients with conventional therapies. Recently, complement inhibitor, the humanized monoclonal anti-C5 antibody eculizumab, complement inhibitor, was approved for patients with anti-AChR antibody-positive generalized refractory MG in Japan. In this review, we focus on the role of complements in the pathogenesis of MG and the action mechanism, efficacy, and future prospects of eculizumab.

PMID:
31171753
DOI:
10.11477/mf.1416201317
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IGAKU-SHOIN Ltd.
Loading ...
Support Center